Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail
Authors not listed
Peking Union Medical College Hospital · 2016
Abstract
The purposes of this study were to investigate the prevalence and risk factors for sarcopenia in Chinese adults and elderly, and evaluate the effect of Lifestyle Modification Project (LMP) on Clinical Outcomes, Quality of Life and Cost-effectiveness Ratio.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
Anonymous. (2016). Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail. <em>Peking Union Medical College Hospital</em>. https://clinicaltrials.gov/study/NCT02873676
Vancouver
Anonymous. Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail. Peking Union Medical College Hospital. 2016.
BibTeX
@misc{anon2016Preval,
title = {Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail},
author = {Anonymous},
journal = {Peking Union Medical College Hospital},
year = {2016},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Abbott Nutrition 2014
Open access · US-GOV
Health Status of Chinese Elderly
WestVac Biopharma Co., Ltd. 2023
Open access · US-GOV
A Randomized, Parallel Controlled, Double-blind, Single-center Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)(WSK-V102) in People Aged 18 Years or Older
Jiangsu Province Centers for Disease Control and Prevention 2021
Open access · US-GOV
A Single-center, Randomized, Double Blinded, Placebo Controlled, Phase 2 Clinical Trial of Recombinant COVID-19 Vaccine (CHO Cells), in the Subjects From Healthy Aged 18 Years and Above
Eman Alaa Eldean Mohamed 2025
Open access · US-GOV
Asessment of Sarcopenia Among Elderly Type 2 Diabetic Patients
Sinovac Life Sciences Co., Ltd. 2020
Open access · US-GOV
A Randomized, Double-blind, Placebo-controlled Clinical Trial, to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cell), in Healthy Elderly Aged 60 Years and Above
Frontiers in Nutrition 2024
Open access · CC-BY